Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q1 FY25 results · Apr–Jun 2024
Panacea Biotec reported revenue from operations of ₹115.72 crore (down 10.4% from Q1 FY24) and net loss of ₹15.88 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 115.72 | 129.19 | −10.4% | 136.46 | −15.2% |
| Other income | 3.80 | 6.08 | −37.5% | 10.81 | −64.8% |
| Total income | 119.52 | 135.27 | −11.6% | 147.27 | −18.8% |
| Profit before tax | (17.05) | 13.03 | Turned loss | (2.12) | Loss widened |
| Net profit for the period | (15.88) | 10.98 | Turned loss | (1.99) | Loss widened |
| Attributable to shareholders of the company | (15.80) | — | — | (1.43) | Loss widened |
| EPS, basic (₹) | (2.59) | 1.79 | Turned loss | (0.23) | Loss widened |
| Net margin (%) | -13.7 | 8.5 | -1.5 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 56.88 | 89.41 | −36.4% | 80.37 | −29.2% |
| Other income | 3.80 | 3.34 | +13.8% | 16.39 | −76.8% |
| Total income | 60.68 | 92.75 | −34.6% | 96.76 | −37.3% |
| Profit before tax | (14.98) | 1.29 | Turned loss | (1.35) | Loss widened |
| Net profit for the period | (13.78) | 1.29 | Turned loss | (1.37) | Loss widened |
| EPS, basic (₹) | (2.25) | 0.21 | Turned loss | (0.22) | Loss widened |
| Net margin (%) | -24.2 | 1.4 | -1.7 |
Consolidated
- Filed with BSE
- 30 Aug 2024, 11:14 IST
- Board meeting
- 14 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Aug 2024, 11:14 IST
- Board meeting
- 14 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE